Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective and Exploratory Study of Optical Coherence Tomography-Assisted Strategy for Interventional Management of Symptomatic Carotid Stenosis

NCT07886775 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT07886775 Not yet recruiting Not applicable 100 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07886775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started November 2026. Interventional study, 100 participants (estimated). Lead sponsor Beijing Tiantan Hospital; China. Primary measure: Any stroke or death from enrollment to 30 days after endovascular treatment of the qualifying artery...

How it compares

119 similar trials: same condition (Carotid Stenosis) and phase

Enrollment

This trial
100
Middle half
42 to 208
Median
100
Trials with a value
119

Months from start to completion

This trial
38
Middle half
19 to 42.6
Median
28.4
Trials with a value
116

Sites

This trial
1
Middle half
1 to 1
Median
1
Trials with a value
103
Posted results or a linked paper 49% 58 of 119 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective and Exploratory Study of Optical Coherence Tomography-Assisted Strategy for Interventional Management of Symptomatic Carotid Stenosis
Lead sponsor
Beijing Tiantan Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
December 31, 2029
Enrollment
100 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
20 Years
Maximum age
80 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
China
Lead sponsor
Beijing Tiantan Hospital

Arms

As registered; 1 arm.

Registered arms
Arm Type Interventions
OCT guided endovascular treatment Experimental OCT guided endovascular treatment
Show registry wording

All the participants will undergo endovascular treatment guided by OCT.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Any stroke or death from enrollment to 30 days after endovascular treatment of the qualifying artery, or ipsilateral ischemic stroke or ischemic driven qualifying artery revascularization during the remaining follow-up period up to 6 months 6 months
Show registry wording

This outcome includes ischemic/hemorrhagic stroke or all-cause death from enrollment to 30 days after endovascular treatment of the qualifying artery, or ipsilateral ischemic stroke or ischemic driven qualifying artery revascularization during the remaining follow-up period up to 6 months.

Lead sponsor's other trials

Beijing Tiantan Hospital, most recent start first.

Similar trials

Same condition (Carotid Stenosis) and phase, most recent start first.